/ / / Asthma Attack Faces Newly Approved Super Treatment ‘Cinqair’

Asthma Attack Faces Newly Approved Super Treatment ‘Cinqair’

, Edit

Asthma Attack Faces Newly Approved Super Treatment 'Cinqair'

Asthma attacks have a new opponent. And from clinical reports, asthma treatment Cinqair may be quite the formidable remedy. Although, there are side effects.

Humans need adequate air flows in order to function properly. Yet, asthma’s objective goes against everything that concerns “proper air flow.” Whether from allergies, wheezing, or asthma’s own chronic symptoms, the condition can hospitalize or even threaten the asthma patient’s life.

So, asthma treatment Cinqair was developed by Teva Pharmaceutical Industries and approved on March 23. According to the pharmaceutical source, this asthma medicine works with existing treatments. However, its significant difference is its potency. Cinqair specifically targets patients with severe, chronic asthma — typically, those who aren’t seeing results with their regular treatment.

The American Academy of Allergy Asthma & Immunology (AAAAI) suggests that there’s no cure for this particular disease condition. However, its usual medication stands as a controller. Specifically, these medications contain inhaled corticosteroids — which AAAAI considers “the most effective long term usage medication for control and management of asthma.” Some examples are as follows:

  • Fluticasone (Flovent Diskus, Flovent HFA)
  • Budesonide (Pulmicort Flexhaler)
  • Mometasone (Asmanex)
  • Beclomethasone (Qvar)
  • Ciclesonide (Alvesco).

Professor Mario Castro of the Washington University School of Medicine states that the issue has been that the aforementioned treatments haven’t successfully controlled severe asthma cases, even by today’s medical standards. However, Cinqair has been developed to assist those asthma medications. The university’s professor mentions that the pharmaceutical company’s new medication makes a significant stride in asthma treatment. He continues as follows.

“As a practicing physician, I look forward to the opportunity to provide my patients, who have severe uncontrolled asthma and fit the profile for Cinqair, with an option that has the potential to help them achieve control of their disease.”

According to Teva Pharmaceutical, the asthma treatment is “an interleukin 5 antagonist monoclonal antibody (IgG4 kappa) indicated for add-on maintenance treatment of patients with severe asthma aged 18 years and older, and with an eosinophilic phenotype.”

The source states that this asthma medication will be commercially available during the second quarter of 2016, but it’s only by prescription. However, Cinqair is administered by intravenous infusion, better known as an I.V. injection. Each asthma treatment dosage is given at a “weight-based dose of 3 mg/kg once every four weeks,” as denotes the pharmaceutical company.

In addition, Michael Hayden — Teva’s Chief Scientific Officer — mentions that medications like this particular asthma treatment targets “unmet needs” within patients, even including healthcare providers and caregivers in essential therapeutic emphases.

While this asthma treatment seems to be the new wonder drug for patients with this disease, it has significant side effects. One of the key side effects is anaphylaxis, which is when your immune system overreacts to particular allergens, says AAAAI. When this happens, the body releases chemicals that cause allergy symptoms.

Although the asthma treatment could produce this life-threatening side effect, there are certain symptoms you might experience beforehand. According to Drugs.com, preemptive reactions to this asthma medication could include any of the following:

  • breathing problems
  • flushing
  • itching
  • symptoms of low blood pressure (fainting, dizziness, light-headedness, confusion, fast heart beat)
  • paleness
  • skin rash (hives)
  • swelling of your face, lips, mouth, or tongue
  • nausea or abdominal discomfort.

However, while this is one key side effect of the asthma treatment, it’s not the only danger. The U.S. Food and Drug Administration notes that Cinqair’s “most common side effects in clinical trials… included anaphylaxis, cancer, and muscle pain.”

While these are possibilities, Drugs.com mentions that — before trying the asthma treatment — you should consult your physician if you have any prior complications.

All in all, will you try this asthma medication? Feel free to share your thoughts in the comments below.

[Photo by Shutterstock]

Asthma Attack Faces Newly Approved Super Treatment ‘Cinqair’ is an article from: The Inquisitr News

Share on Google Plus
    Blogger Comment
    Facebook Comment

0 comments :

Post a Comment

Subscribe to: Post Comments ( Atom )